https://scholars.lib.ntu.edu.tw/handle/123456789/512196
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lai C.-C. | en_US |
dc.contributor.author | Wang Y.-H. | en_US |
dc.contributor.author | Wang C.-Y. | en_US |
dc.contributor.author | HAO-CHIEN WANG | en_US |
dc.contributor.author | CHONG-JEN YU | en_US |
dc.contributor.author | Chen L. | en_US |
dc.contributor.author | Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE) | en_US |
dc.date.accessioned | 2020-08-12T07:46:58Z | - |
dc.date.available | 2020-08-12T07:46:58Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1176-9106 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044382573&doi=10.2147%2fCOPD.S158634&partnerID=40&md5=b26552565601e59dc1df90c81ccbf377 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/512196 | - |
dc.description.abstract | Objectives: This study aimed to compare the effects of angiotensin-converting-enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) on the risk of pneumonia and severe exacerbations in patients with COPD. Patients and methods: All patients with COPD who used ACEis and ARBs for >90 days between 2000 and 2005 were recruited. Pairwise matching (1:1) of the ACEi and ARB groups resulted in two similar subgroups, with 6,226 patients in each. The primary outcomes were pneumonia and COPD exacerbations, and the secondary outcome was death. Results: During the follow-up period, the incidence of pneumonia was 7.20 per 100 person-years in the ACEi group and 5.89 per 100 person-years in the ARB group. The ACEi group had a higher risk of pneumonia (adjusted hazard ratio [aHR], 1.22; 95% CI, 1.15–1.29) than the ARB group. The incidence of severe exacerbations was 0.65 per person-year for the patients receiving ACEis and 0.52 per person-year for those receiving ARBs. The patients receiving ACEis had a higher risk of severe exacerbations (aHR, 1.19; 95% CI, 1.16–1.21) than those receiving ARBs. Similar trends were noted in terms of severe exacerbations requiring hospitalization (aHR, 1.24; 95% CI, 1.21–1.28) or emergency department visits (aHR, 1.16; 95% CI, 1.13–1.18), pneumonia requiring mechanical ventilation (aHR, 1.35; 95% CI, 1.24–1.47), and mortality (aHR, 1.33; 95% CI, 1.26–1.42). Conclusion: ARBs were associated with lower rates of pneumonia, severe pneumonia, and mortality than ACEis in patients with COPD. ? 2018 Lai et al. | - |
dc.publisher | Dove Medical Press Ltd. | - |
dc.relation.ispartof | International Journal of COPD | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; angiotensin 1 receptor antagonist; dipeptidyl carboxypeptidase inhibitor; aged; Article; artificial ventilation; chronic obstructive lung disease; cohort analysis; comparative effectiveness; controlled study; death; disease association; disease exacerbation; drug sensitivity; emergency ward; female; follow up; high risk population; hospitalization; human; incidence; major clinical study; male; mortality rate; outcome assessment; pneumonia; treatment duration; administrative claims (health care); chronic obstructive lung disease; comparative study; disease exacerbation; factual database; middle aged; mortality; pneumonia; prognosis; proportional hazards model; protection; risk assessment; risk factor; Taiwan; time factor; Administrative Claims, Healthcare; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Databases, Factual; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; Pneumonia; Prognosis; Proportional Hazards Models; Protective Factors; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Risk Factors; Taiwan; Time Factors | - |
dc.title | Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.2147/COPD.S158634 | - |
dc.identifier.pmid | 29563786 | - |
dc.identifier.scopus | 2-s2.0-85044382573 | - |
dc.relation.pages | 867-874 | - |
dc.relation.journalvolume | 13 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | National Taiwan University Hospital Hsin-Chu Branch | - |
crisitem.author.dept | NTU BioMedical Park Hospital | - |
crisitem.author.orcid | 0000-0002-7528-7494 | - |
crisitem.author.orcid | 0000-0001-5664-9392 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital Hsin-Chu Branch | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。